Synthetic Biologics Inc (SYN) Given Consensus Rating of “Hold” by Analysts
Shares of Synthetic Biologics Inc (NYSEMKT:SYN) have been assigned a consensus rating of “Hold” from the seven analysts that are currently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating on the company. The average twelve-month price target among brokers that have covered the stock in the last year is $4.39.
A number of analysts have commented on the company. ValuEngine upgraded Synthetic Biologics from a “strong sell” rating to a “sell” rating in a research report on Friday, August 18th. Zacks Investment Research upgraded Synthetic Biologics from a “hold” rating to a “buy” rating and set a $0.75 price target for the company in a research report on Wednesday, August 9th. Finally, William Blair restated an “outperform” rating and issued a $5.00 price target on shares of Synthetic Biologics in a research report on Monday, May 22nd.
Hedge funds have recently added to or reduced their stakes in the company. Creative Planning boosted its stake in Synthetic Biologics by 65.4% in the second quarter. Creative Planning now owns 177,000 shares of the company’s stock valued at $100,000 after buying an additional 70,000 shares in the last quarter. Susquehanna International Group LLP boosted its stake in Synthetic Biologics by 76.4% in the second quarter. Susquehanna International Group LLP now owns 189,342 shares of the company’s stock valued at $107,000 after buying an additional 82,030 shares in the last quarter. UBS Group AG boosted its stake in Synthetic Biologics by 10.3% in the first quarter. UBS Group AG now owns 214,357 shares of the company’s stock valued at $135,000 after buying an additional 20,038 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in Synthetic Biologics by 3.1% in the first quarter. Bank of New York Mellon Corp now owns 263,598 shares of the company’s stock valued at $166,000 after buying an additional 7,962 shares in the last quarter. Finally, LMR Partners LLP acquired a new stake in Synthetic Biologics during the second quarter valued at about $194,000.
Shares of Synthetic Biologics (NYSEMKT:SYN) opened at 0.635 on Tuesday. Synthetic Biologics has a 12 month low of $0.41 and a 12 month high of $1.90. The company’s market cap is $81.44 million. The stock has a 50 day moving average of $0.55 and a 200-day moving average of $0.62.
Synthetic Biologics (NYSEMKT:SYN) last issued its quarterly earnings results on Thursday, August 3rd. The company reported ($0.03) EPS for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.03. Equities analysts forecast that Synthetic Biologics will post ($0.17) earnings per share for the current year.
About Synthetic Biologics
Synthetic Biologics, Inc is a clinical-stage company. The Company is engaged in developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases. The Company’s lead product candidates in Phase II development are SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C), and SYN-004, which is designed to protect the gut microbiome (gastrointestinal (GI) microflora) from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C.
Receive News & Ratings for Synthetic Biologics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthetic Biologics Inc and related companies with MarketBeat.com's FREE daily email newsletter.